logo

Arrowhead Pharmaceuticals Inc. (ARWR)



Trade ARWR now with
  Date
  Headline
8/8/2019 7:32:58 AM Arrowhead Pharma Doses First Patient In SEQUOIA Phase 2/3 Study Of ARO-AAT For Alpha-1 Liver Disease
7/16/2019 4:09:44 PM Arrowhead: FDA Granted Orphan Drug Designation To ARO-ANG3 For HoFH Treatment
6/27/2019 7:34:09 AM Arrowhead Pharma Receives Fast Track Designation For ARO-AAT For Alpha-1 Liver Disease
6/21/2019 7:33:41 AM Arrowhead Says FDA Granted Orphan Drug Designation To ARO-APOC3
5/8/2019 4:03:59 PM Arrowhead Pharmaceuticals Q2 EPS $0.24 Vs Loss $0.18 Prior Year
4/15/2019 7:37:50 AM Arrowhead Secures FDA Clearance To Begin Phase 2/3 Study Of ARO-AAT
3/18/2019 7:35:16 AM Arrowhead Pharma Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Alpha-1 Liver Disease
3/11/2019 7:40:57 AM Arrowhead Doses First Subjects In Phase 1 Clinical Study Of ARO-APOC3
1/7/2019 7:38:47 AM Arrowhead Begins Dosing In Phase 1 Study Of ARO-ANG3 For Treatment Of Dyslipidemias And Metabolic Diseases
1/7/2019 7:37:25 AM Arrowhead Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia
10/31/2018 7:37:36 AM Arrowhead Reports Closing Of Agreements With Janssen
10/17/2018 7:18:43 AM William Blair Reiterates Arrowhead Pharmaceuticals Inc. (ARWR) At Outperform
10/15/2018 7:31:18 AM Arrowhead Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-ANG3
10/4/2018 7:44:08 AM Arrowhead Enters $3.7 Bln License And Collaboration Agreements With Janssen
9/6/2018 7:31:46 AM Arrowhead Presents New ARO-HBV Clinical Data Showing HBsAg Reductions At World Gastroenterologists Summit